Medical evidence is outpacing diligence. Zemi turns it into decision-grade dossiers.

Links MRD timing, antigen selection, vaccine manufacture, immune response, and recurrence endpoints into a recurrence-prevention decision gate.

Separates IO platform promise from therapeutic-index reality across potency, specificity, resistance, safety, and combination logic.

Distinguishes remission achieved from durability solved by mapping persistence, sanctuary, and immune reconstitution risks.

Identifies the rate-limiting resolution node and the matched research move across persistence, scar integrity, and reversal measurement.

Routes immune-aging programs to the binding supply-chain node before treating broad immune decline as one therapeutic target.

Classifies whether mitotic dilution, active erasure, or reactivation pressure will dominate before buyers commit to delivery, indication, or permanence strategy.

Turns in-vivo editing from a modality story into a coupled-system failure-mode map.

Positions RNA editing on a permanence spectrum so buyers do not confuse reversibility with durability or safety by default.

Uses molecular mechanism rather than gene label to route programs toward addition, knockdown, editing, or avoidance logic.

Maps fungal threat expansion against diagnostic timing, drug scarcity, resistance, toxicity, and host-risk stratification.

Uses mutational supply, diagnostic timing, pathogen burden, and combination logic to assess durability against resistance escape.

Routes variant interpretation toward rescue experiments instead of stopping at association, prediction, or annotation confidence.

Maps mitochondrial interventions onto a permanence ladder so buyers do not overbuild or underbuild the required correction.

Separates static generation wins from the harder validation problem: whether AI can predict dynamic biological response under prospective tests.

Turns AI and digital biomarkers into validation-gate questions: prospective utility, generalization, drift, fairness, and endpoint acceptance.

Diagnoses whether BCI/BSI decline is recoverable code drift or irreversible source loss before buyers overspend on the wrong layer.

Scores indication readiness by biomarker validity, sensing fidelity, decoding generalizability, circuit match, and substitution economics.

Resolves the Lost-vs-Locked diagnostic gate before choosing re-access, editing, stabilization, reconstruction, or avoidance.

Uses convergent detection to subtype disease, while requiring sign-labile biology and therapeutic-window logic before treatment spend.

Routes a proposed context of use to its binding qualification gate before buyers spend on biological completeness.

Separates endocrine, follicular, mitochondrial, stromal, and functional clocks before buyers infer benefit from measurement movement.

Maps the rejuvenation-transformation margin so buyers can distinguish clock movement from functional, controlled, and safe benefit.

Evaluates whether vascular networks are merely visible, truly perfusable, functionally mature, and integration-ready.

Maps the durability ceiling across host tolerance, organ-specific failure physiology, immune compatibility, and organ-scale function.